InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,495.18
(
-0.21%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
-0.61%
)
Bitcoin
69,417.38
(
-1.90%
)
Post# of 113515
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

RNsidersbuying

Send PM Follow Ignore
Followers 46
Posts 4479
Boards Moderated 0
Alias Born 07/26/2010

RNsidersbuying

Re: nelson1234 post# 90328

Wednesday, 08/25/2021 4:17:30 PM

Wednesday, August 25, 2021 4:17:30 PM

Post# of 113515
GLYC 1.99 - traded it a couple times recently for a few pennies, several irons in the fire, and remains high on my biobust watchlist.

"There are now six trials underway evaluating our lead clinical candidate, uproleselan, including three registration trials and three ISTs, which we anticipate will provide clinical data flow beginning in 2022.

https://docoh.com/news/benzinga/22346501/glycomimetics-reports?fromCompany=1253689

A few months ago, I'd have been way more aggressive at this pps in GLYC, but I'm convinced the indexes are waaaayyyyyy too high. And it's even probable that the robinhooligans will be just as overeager in their eventual selling as they've shown to be in their overeager buying???

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up